| INTRODUCTION
The prevalence of obesity and IBD is increasing in parallel; approximately 15%-40% of patients with IBD are obese and up to 66% are overweight. [1] [2] [3] [4] Obesity has been associated with increased risk of developing Crohn's disease, but not ulcerative colitis (UC). 5, 6 Obesity has been variably associated with IBD phenotype, with some studies suggesting milder disease and others suggesting lower prevalence of remission in cross-sectional studies. 7, 8 Longitudinal studies have suggested that obesity is associated with inferior quality of life, higher burden of hospitalisation and healthcare utilisation, and higher risk of relapse; among patients who undergo surgery, obesity has been associated with increased risk of short-term complications. [2] [3] [4] 8 Population pharmacokinetic studies of biologic agents have consistently shown that higher body weight is associated with increased drug clearance and lower trough concentrations. [9] [10] [11] However, clinical studies of obesity's impact on response to biologic agents in patients with IBD have been sparse and conflicting. In their cohort of 261 infliximab-treated patients, Billiet and colleagues observed that each unit increase in BMI was associated with 6% higher risk of treatment failure only on univariate analysis, but not on multivariate analysis. 12 In contrast, Bultman and colleagues observed that obesity
) is associated with increased need for adalimumab dose escalation. 13 Most of the studies have been performed in patients with Crohn's disease, with only a single, 24-patient study in infliximab-treated patients with UC. 14 Given higher drug clearance and faecal wasting in patients with severe UC compared to Crohn's disease, obesity may be more relevant in biologic-treated patients with UC. 15, 16 Hence, we conducted a retrospective cohort study to evaluate the impact of obesity on response to biologic therapy in patients with UC. We hypothesised that higher BMI is associated with an increased risk of treatment failure in biologic-treated patients with UC, particularly in a subset of patients treated with fixed-dose regimens.
2 | ME TH ODS
| Study design
We performed a retrospective cohort study in biologic-treated patients with UC seen and followed at University of California San Diego (UCSD). Patients were included if they had UC, were new users of a biologic agent (anti-tumour necrosis factor-a [TNF] agent such as infliximab, adalimumab or golimumab, or anti-integrin agent, vedolizumab) between January 1, 2011 and December 31, 2016, were followed at UCSD for at least 6 months, and had a BMI recorded within 3 months of start of biologic therapy. Patients were excluded if they: (1) had Crohn's disease or indeterminate colitis, (2) were not treated with biologic agents, (3) were followed at UCSD for <6 months, (4) were underweight with BMI <18.5 kg/m 2 at time of cohort entry, (5) were pregnant or (6) had already undergone colectomy prior to starting biologic therapy. Prevalent users of biologic agents (ie patients who were already on a biologic agent at time of study start date) were also excluded to minimise immortal time bias. This study was approved by the UCSD Institutional Review Board (IRB #160967).
| Data abstraction
A single reviewer (SK) abstracted data through medical record review using a piloted data abstraction form, with constant feedback from a second gastroenterologist reviewer (SS 
| Exposure
The primary predictor variable was BMI as a continuous variable.
We evaluated the association between each 1 kg/m 2 increase in BMI and clinical outcomes. Additionally, we performed post-hoc analysis evaluating the association between biologic trough concentration and BMI. At our centre, routine proactive therapeutic drug monitoring (TDM) is not performed for all patients with quiescent IBD; instead, providers variably perform reactive TDM in patients failing therapy, and in selected patients with quiescent disease.
| Outcomes

| Statistical analysis
We performed univariate time-to-event analysis or logistic regression 3 | RESULTS Approximately 61% patients had pancolitis, and 53% had severely active endoscopic disease. Approximately 73% patients were biologic-na€ ıve at time of cohort entry, 55.0% treated with infliximab (weight-based therapy) and 18.8% were treated with vedolizumab.
| Patient characteristics
About 53% and 52% were concomitantly on immunomodulators and corticosteroids, respectively, and 81% had used corticosteroids in the last 1 year prior to initiation of biologic therapy. Over a median follow-up of 2 years after starting biologic therapy, 110 patients experienced treatment failure, 23 patients underwent surgery and 41 patients experienced IBD-related hospitaliszation. All patients with "treatment failure" underwent treatment modification as the primary reason for treatment failure; within treatment modification, initiation of corticosteroids was the most common intervention.
These have been detailed in Table S1 .
| Primary outcome
On multivariate analysis, each 1 kg/m 2 increase in BMI was associated with a 4% higher risk of treatment failure (aHR, 1.04; 95% CI, 1.00-1.08, P = 0.029). This effect was similar in patients treated with weight-based therapy (aHR, 1.05; 95% CI, 1.00-1.10, P = 0.050) and in patients treated with fixed-dose therapy (aHR, 1.05; 95% CI, 0.99-1.10, P = 0.106) (Figure 1 ). Besides BMI, low albumin and shorter disease duration were associated with treatment failure ( 
| Endoscopic remission
Although not significant, each 1 kg/m 2 increase in BMI was associated with 6% lower risk of achieving endoscopic remission (aOR, 0.94; 95% CI, 0.87-1.01, P = 0.070), though it did not meet statistical significance. This negative effect was significant only in patients treated with weight-based therapy (aOR, 0.91; 95% CI, 0.83-0.99, P = 0.035), but not in patients treated with fixed-dose therapies (aOR, 0.96; 95% CI, 0.85-1.10, P = 0.571) (Figure 1 ). Besides BMI, patients with longer disease duration were significantly more likely to achieve endoscopic remission (aOR, 1.12; 95% CI, 1.04-1.21, 
| DISCUSSION
In this retrospective study on the impact of BMI on treatment response and outcomes in 160 biologic-treated patients with UC, we made several key observations. First, we found that higher BMI is independently associated with an increased risk of treatment failure and IBD-related surgery and/or hospitalisation, with each unit increase in BMI being associated with a 4%-8% higher risk of adverse outcomes. This effect of BMI is independent of biologic dosing regimen, observed in patients treated with either weight-based dosed infliximab or other fixed-dose therapies. Second, we also observed that higher BMI may be independently associated with failure to achieve endoscopic remission, though this outcome did not reach statistical significance. Our findings suggest that obesity is a negative prognostic factor in biologic-treated patients with UC and a treatment effect modifier that must be considered in clinical trial design and clinical practice. Our findings build upon an evolving and conflicting body of evidence on the potential negative impact of obesity in patients with IBD, in particular its impact on treatment response to biologics. [18] [19] [20] While obesity has been consistently shown to negatively impact treatment response to anti-TNF agents in rheumatic diseases, this evidence has been inconsistent in patients with IBD. In a meta-analysis of 16 studies with 3130 patients with IBD, we observed that obesity does not significantly influence treatment response to anti-TNF agents (odds of failing therapy, 1.20; 95% CI, 0.88-1.64). 21 However, there is considerable heterogeneity with differences in study design, obesity exposure categories, clinical outcomes and variable adjustment for key confounding variables. Moreover, most of these studies have been conducted in patients with Crohn's disease. It is possible that in patients with Crohn's disease, local mesenteric creeping fat may play a more vital role in pathogenesis than systemic obesity. 22, 23 In contrast, there has been limited assessment of the impact of obesity on response to biologic agents in patients with UC. In a study of 24 patients with UC treated with infliximab,
Harper and colleagues observed a 30% increase in risk of UC flare per unit increase in BMI, adjusting for prior surgery, steroid use, extra-intestinal manifestations, age and disease duration. However, due to the small sample size, this multivariate model was likely overfitted. 14 Subgroup analysis of ULTRA-2 trial of adalimumab in UC observed a nonsignificant 1.5-fold higher risk of failing to achieve clinical remission in patients weighing ≥70 kg vs <70 kg. 24 Obesity is recognised as a perpetual state of chronic low-grade inflammation, through systemic and paracrine increase in levels of cytokines, chemokines and adipokines, and is also associated with dysbiosis. 4, 22, 23 Obesity increases leptin secretion from adipocytes and resistin secretion from macrophages and leukocytes that increase levels of pro-inflammatory cytokines such as TNF, interleukin-1 and -6. Besides its direct impact on inflammation, obesity can also modify pharmacokinetics of biologic agents. Population pharmacokinetic studies of all approved biologic agents in IBD have identified high body weight as a risk factor associated with increased clearance of drug, resulting in shorter half-life and lower serum trough drug concentrations. [9] [10] [11] This effect might be related to rapid proteolysis and to a "TNF-sink" phenomenon with higher inflammatory burden due to adipose tissue in patients with obesity. This may explain why patients with obesity treated even with weight-based regimens such as infliximab, had inferior response to therapy.
Our study is one of the largest studies evaluating the impact of BMI on treatment response to biologics in patients with UC, with systematic data collection and evaluation of patient-important outcomes. By limiting analyses to new users of biologics followed at our centre and by adjusting for key confounders, we were able to overcome potential limitations of a tertiary referral centre retrospective cohort study. However, our study has some limitations which merit attention. First, our data on association between BMI and biologic trough concentrations needs to be interpreted with caution, since routine biologic trough concentration assessments
were not performed, and drug clearance estimates were not per- cohort studies in patients with psoriasis, psoriatic arthritis and rheumatoid arthritis have suggested a beneficial effect of intentional weight loss on treatment response to anti-TNF agents. [22] [23] [24] [26] [27] [28] In conclusion, in a cohort of biologic-treated patients with UC, we observed that high BMI is independently associated with increased risk of treatment failure, including IBD-related surgery or hospitalisation, and may be a lower risk of achieving endoscopic remission. These effects were seen in patients treated with weight-based dosing regimens as well as fixed-dose agents.
Prospective cohort studies and post-hoc analyses of RCTs with individual participant level data are warranted to confirm this association. If this effect is consistent, interventional studies targeting obesity should be explored for difficult-to-treat obese patients with UC.
